logo-loader
viewStarpharma Holdings Limited

Starpharma Holdings' cabazitaxel is second DEP product to enter clinical stage

DEP® cabazitaxel has already delivered impressive pre-clinical results.

Picture of a laboratory
The alternative Jevtana sales are tipped to reach approximately US$500 million this year

Starpharma Holdings Limited’s (ASX:SPL) (OTCQX:SPHRY) approval to commence its phase I/II clinical trial for DEP® cabazitaxel is an important milestone.

The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® cabazitaxel.

This is central to defining a recommended phase II dose (RP2D), and then to determining anti-tumour efficacy of the product in select tumour types.

Transitions DEP® product from portfolio to clinic

The approval advances DEP® cabazitaxel, Starpharma’s second DEP® product, from its internal portfolio to the clinic.

DEP® cabazitaxel has already delivered impressive pre-clinical results showing sustained efficacy and survival benefits.

it has also eliminated neutropenia, which is a significant dose-limiting side effect of many anti-cancer drugs, including Jevtana®.

Jevtana® sales expected to reach circa US$500 million

DEP® cabazitaxel is Starpharma’s detergent-free version of cancer drug, Jevtana®, which is marketed by global pharmaceutical group Sanofi Aventis.

It is used in the treatment of advanced prostate cancer.

The drug is also under clinical development for a range of other cancer types, including testicular, ovarian, breast, bladder, and head and neck.

Jevtana® sales are estimated to reach approximately US$500 million this year.

Follows success of DEP® docetaxel

DEP® cabazitaxel is the second product from Starpharma’s DEP® platform to enter the clinic.

It follows DEP® docetaxel, which delivered positive phase I clinical results in 2017 and recently progressed to phase II.

The reproducible benefits observed for DEP® docetaxel and DEP® cabazitaxel in pre-clinical models included decreased bone marrow toxicity and enhanced efficacy.

In both cases DEP® has also allowed for a detergent-free formulation resulting in significant additional benefits for patients. 

Quick facts: Starpharma Holdings Limited

Price: 1.27 AUD

ASX:SPL
Market: ASX
Market Cap: $472.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Piedmont Lithium secures landmark Section 404 Permit to...

Piedmont Lithium Ltd (ASX:PLL) CEO Keith Phillips tells Proactive the lithium explorer has received the Section 404 Permit under the Clean Water Act from the US Army Corps of Engineers for its lithium project in North Carolina. Phillips says this landmark achievement follows a fair, albeit...

2 days, 5 hours ago

2 min read